THE TEXAS HEART INSTITUTE® JOURNAL

Erratum

Production Oversight

In the article titled "Anticoagulation Management in Temporary Mechanical Circulatory Support Devices,"[1] published July 21, 2023, minor corrections to the final text should have been incorporated.

Introduction, sentence 5

The TandemHeart manufacturer was identified as *LivaNova*, and this has now been corrected to *CardiacAssist, Inc*.

Current Recommendations, Extracorporeal Membrane Oxygenation, column 2

Original

> However, viscoelastic assays need to be studied further before they can be recommended for widespread use in *the cardiac critical care unit with* UFH in patients receiving ECMO. *Existing* studies have shown lower rates of mortality, transfusions, thrombosis, bleeding, and cost; *however*, the Extracorporeal Life Support Organization states that large and prospective randomized trials are needed before *recommending* bivalirudin as the primary anticoagulant.[6,8-10] A summary of recommendations can be found in Table I.

Correction

> However, viscoelastic assays need to be studied further before they can be recommended for widespread use in *monitoring* UFH in patients receiving ECMO. *Multiple studies have been published comparing the use of bivalirudin with UFH in patients receiving ECMO, and these* studies have shown lower rates of mortality, transfusions, thrombosis, bleeding, and cost. The Extracorporeal Life Support Organization states, *however,* that large and prospective randomized trials are needed before *it can recommend* bivalirudin as the primary anticoagulant.[6,8-10] A summary of recommendations can be found in Table I.

The online article and PDF have been corrected.

Published: 24 August 2023

References

1. Yin EB. Anticoagulation management in temporary circulatory support devices. *Tex Heart Inst J.* 2023;50(4):e238135. doi:10.14503/THIJ-23-8135